Dendreon (DNDN) Announces CMS Will Now Cover Costs Related to Administration of PROVENGE
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
Dendreon (Nasdaq: DNDN) announces the Centers for Medicare and Medicaid Services will now cover infusion costs related to the administration of PROVENGE.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Virtus Investment Partners names Jack Boyce to its board
- Genworth Financial CEO returns from leave of absence in September
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
